Article
Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report.
Journal of investigative medicine high impact case reports - 1 Jan 2000
Al-Nusair Jowan, Bodiwala Reesha, Nwanwene Kemnasom, Abdallah Mahmoud, Alshal Mohamed, Pacioles Toni
Abstract excerpt
Lung cancer, a leading cause of cancer mortality, often involves epidermal growth factor receptor (EGFR) mutations, common in 17% of Caucasian and 40% of Asian non-small-cell lung cancer (NSCLC) patients. While the exon 19 deletion and L858R mutation are prevalent, rare variants like L833V/H835L are less understood. This case reports a 75-year-old female with NSCLC harboring L833V/H835L mutations. Initial imaging...
Topics
- Humans
- Aniline Compounds
- Acrylamides
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Female
- ErbB Receptors
- Aged
- Mutation
- Antineoplastic Agents
- Positron-Emission Tomography